# A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

> **NCT03301090** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 48 (actual)

## Conditions studied

- Corona Virus Infection

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** REGN3048
- **BIOLOGICAL:** REGN3051

## Key facts

- **NCT ID:** NCT03301090
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2019-01-19
- **Final completion:** 2019-01-19
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301090, "A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03301090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*